ISSN:1172-8299    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

Having received approval for a drug, companies now need to assess the additional information requirements that exist in the current environment of cost consciousness. Previously, US companies were only concerned with supplying adequate data on efficacy and tolerability to the FDA, but now there is a demand for cost-effectiveness information that can denote the value of a drug to managed care players. Speakers at the FDA-sponsored meeting‘Comparing Treatments: Safety, Effectiveness and Cost Effectiveness’[Bethesda, US; March 1995] discussed these new information requirements, and presented the latest US guidelines on how to conduct relevant studies.

ISSN:1172-8299    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1172-8299    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1172-8299    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1172-8299    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1172-8299    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

The key to the successful strategic use of pharmacoeconomic research is making sure we do not develop relatively sophisticated, scientific answers to irrelevant questions, said Dr Leandro Herrero, Vice-president of Research & Development Europe, Allergan, atOutcomes '95[Washington, DC, US; March 1995]. Talking about the strategic use of pharmacoeconomics, he emphasised that the correct question must be askedbeforeattention is turned to study methodology. While everyone recognises the importance of defining the question, far less time is committed to this vital step than to determining study methodology.

ISSN:1172-8299    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1172-8299    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1172-8299    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1172-8299    

出版商:ADIS    

年代:1995

数据来源: ADIS